{'fraction_non_alphanumeric': 0.050029429075927015, 'fraction_numerical': 0.05709240729841083, 'mean_word_length': 4.345911949685535, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A retrospective analysis of treatment in triple-negative brest cancer (TNBC).

e11623 Background: TNBC makes about 12.5% of all breast cancer. TNBC show have a poor prognosis due to the aggressive biology with relative resistance to systemic therapies. 85% of TNBC are basal-like subtype. Basal-like TNBC are diagnosed by a positive CK5/14 stainig in immunohistochemical staining.


METHODS
200 pts with TNBC in Bayreuth hospital were analysed retrospectively between 1995 and 2006. 52/200 (26%) pts underwent primary systemic therapy (PST). 6/200 pts primary had stage IV disease. In 49 pts ck 5/14 staining was done.


RESULTS
The median follow up 56 mts, median age at diagnosis was 52 yrs. At the time of analysis 146/200 pts were alive. DFS was 25 mts, OS 44 mts. 7/42 (16. 6%) had a pathological complete response rate (pCR) after PST, in 5/7 pts PST was based on anthracyclines. The estimated residual tumor size in preoperative MR correlated strongly with the histopathological tumor size (Pearson Correlation r=0,81, p< 0.01). Stage IV patients with viszeral disease had a median age of 69 yrs and median OS 6,3 (2-12 mts). Overall recurrence rate was 24% (48/200 pts). Grading in all TNBC variated (G1: 7 pts (3,5%), G2: 52 pts (26%), G3: 132 pts (66%).


CONCLUSIONS
The retrospective data demonstrate that basal-like TNBC is an important subgroup with a poor prognosis. In future it will be important to pick up these subgroup to bring them to different therapies. Preoperative MR is a good tool to predict the residual tumor size after PST in all TNBC pts. Anthracycline-based systemic therapy is still standard in adjuvant treatment. No significant financial relationships to disclose.